• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Heartflow Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure

    9/10/25 7:30:20 AM ET
    $HTFL
    Medical/Dental Instruments
    Health Care
    Get the next $HTFL alert in real time by email
    htfl-20250910
    false000146452100014645212025-09-102025-09-10

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549
    FORM 8-K
    CURRENT REPORT
    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
    Date of Report (Date of earliest event reported): September 10, 2025
    Heartflow, Inc.
    (Exact name of Registrant as Specified in Its Charter)
    Delaware001-4279026-0506743
    (State or Other Jurisdiction
    of Incorporation)
    (Commission File Number)
    (IRS Employer
    Identification No.)

    331 E. Evelyn Avenue
    Mountain View, California 94041
    (Address of Principal Executive Offices) (Zip Code)
    (650) 241-1221
    (Registrant’s Telephone Number, Including Area Code)
    N/A
    (Former Name or Former Address, if Changed Since Last Report)
    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
    oWritten communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    oSoliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    oPre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    oPre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
    Securities registered pursuant to Section 12(b) of the Act:
    Title of each class
    Trading Symbol(s)
    Name of each exchange on which registered
    Common Stock, $0.001 par value per shareHTFL
    The Nasdaq Stock Market LLC
    (Nasdaq Global Select Market)
    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
    Emerging growth company x
    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o



    Item 2.02 Results of Operations and Financial Condition.

    As previously disclosed, Heartflow, Inc. (the “Company”) will participate at the Morgan Stanley 23rd Annual Global Healthcare Conference today, September 10, 2025. In connection with meetings with investors at the conference, the Company has published an Investor Presentation on its website as described in Item 7.01 below (the “Investor Presentation”).

    In the Investor Presentation, the Company discloses the following preliminary unaudited results of operations for the three months ended June 30, 2025, which were initially disclosed as ranges in the Company’s Registration Statement on Form S-1 (File No. 333-288733) filed with the U.S. Securities and Exchange Commission (“SEC”) in connection with the Company’s initial public offering completed on August 11, 2025: (i) revenue is expected to be approximately $43.4 million, (ii) gross margin is expected to be approximately 75.5%, and (iii) operating expenses are expected to be approximately $46.5 million. In addition, the Company will disclose that its cash and cash equivalents balance was approximately $80.2 million as of June 30, 2025, which does not give effect to the net proceeds to the Company of approximately $333.0 million upon the closing of its initial public offering or the repayment in full during the three months ended September 30, 2025 of all amounts outstanding under the Company’s Credit Agreement and Guaranty with Hayfin Services LLP and other parties thereto (comprising $114.1 million as of June 30, 2025) plus accrued interest and related fees thereon.

    The financial information presented in this Item 2.02 is preliminary and unaudited based on the most recent information available to the Company’s management as of the date hereof and does not reflect a comprehensive statement of the Company’s financial results as of and for the three months ended June 30, 2025, which will be disclosed in the Company’s Quarterly Report on Form 10-Q when filed with the SEC. Actual results for the three months ended June 30, 2025 may differ from this preliminary information as a result of completion of the quarterly review of the Company’s consolidated financial statements for the three months ended June 30, 2025, including final adjustments, the review by the Company’s independent registered public accounting firm, and other developments that may arise between now and the filing of the Quarterly Report on Form 10-Q.

    Item 7.01 Regulation FD Disclosure.

    In connection with the Morgan Stanley 23rd Annual Global Healthcare Conference, the Company is publishing the Investor Presentation on the Investors page of the Company’s website at https://ir.heartflow.com.

    The information contained in Items 2.02 and 7.01 to this Current Report on Form 8-K shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.



    SIGNATURES
    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
    HEARTFLOW, INC.
    Date: September 10, 2025By:/s/ Vikram Verghese
    Vikram Verghese
    Chief Financial Officer

    Get the next $HTFL alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $HTFL

    DatePrice TargetRatingAnalyst
    9/2/2025$36.00Overweight
    Analyst
    9/2/2025$38.00Overweight
    Piper Sandler
    9/2/2025$35.00Buy
    Stifel
    9/2/2025$35.00Buy
    Canaccord Genuity
    9/2/2025$35.00Equal-Weight
    Morgan Stanley
    More analyst ratings

    $HTFL
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Calyxo Expands Board of Directors as Number of Patients Treated with its CVAC® System Crosses 20,000 Milestone

    -- Dana G. Mead, Jr. brings 30 years of expertise in product strategy, development and commercialization to the Calyxo boardroom, as the company marks its next stage of growth. -- More than 20,000 patients have been treated with the CVAC System, underscoring the increasing adoption of the SURE procedure and its impact in kidney stone care. Calyxo, Inc., a medical device company advancing innovative solutions for kidney stone treatment, marked key milestones as adoption of the steerable ureteroscopic renal evacuation (SURE) procedure using the company's CVAC System continues to accelerate. The company has appointed Dana G. Mead, Jr. to its board of directors, and it has reached more than

    10/8/25 8:00:00 AM ET
    $HTFL
    $INSP
    $LUNG
    Medical/Dental Instruments
    Health Care
    Medical/Nursing Services

    Heartflow Announces FDA 510(k) Clearance and Launch of Next Generation Heartflow Plaque Analysis Platform

    MOUNTAIN VIEW, Calif., Sept. 22, 2025 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (NASDAQ:HTFL), the leader in AI technology for coronary artery disease (CAD), today announced it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its Next Gen Heartflow Plaque Analysis algorithm and the platform is now available. The technology features an updated algorithm, vastly expanded nomogram, and advanced 3D color-coded visualization of plaque type, volume, and distribution, empowering clinicians with the insights needed to make confident care decisions with ease. Heartflow also announced that Heartflow Plaque Analysis will be covered by Cigna across all of its lines of bu

    9/22/25 4:05:00 PM ET
    $HTFL
    Medical/Dental Instruments
    Health Care

    Heartflow to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference

    MOUNTAIN VIEW, Calif., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (NASDAQ:HTFL), the leader in AI technology for coronary artery disease (CAD), today announced that members of management will participate in a fireside chat at the upcoming Morgan Stanley 23rd Annual Global Healthcare Conference. The fireside chat will take place on Wednesday, September 10, 2025, at 6:15 a.m. PT / 9:15 a.m. ET. A live and archived version of the fireside chat will be available on the Investor Relations section of the Heartflow website at https://ir.heartflow.com. About Heartflow, Inc.Heartflow is advancing coronary care by transforming coronary artery disease into a screenable, diagnosab

    8/27/25 4:24:48 PM ET
    $HTFL
    Medical/Dental Instruments
    Health Care

    $HTFL
    SEC Filings

    View All

    SEC Form 10-Q filed by Heartflow Inc.

    10-Q - Heartflow, Inc. (0001464521) (Filer)

    9/19/25 8:31:10 AM ET
    $HTFL
    Medical/Dental Instruments
    Health Care

    Heartflow Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure

    8-K - Heartflow, Inc. (0001464521) (Filer)

    9/10/25 7:30:20 AM ET
    $HTFL
    Medical/Dental Instruments
    Health Care

    Heartflow Inc. filed SEC Form 8-K: Termination of a Material Definitive Agreement

    8-K - Heartflow, Inc. (0001464521) (Filer)

    8/25/25 4:03:57 PM ET
    $HTFL
    Medical/Dental Instruments
    Health Care

    $HTFL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Analyst initiated coverage on Heartflow with a new price target

    Analyst initiated coverage of Heartflow with a rating of Overweight and set a new price target of $36.00

    9/2/25 8:38:06 AM ET
    $HTFL
    Medical/Dental Instruments
    Health Care

    Piper Sandler initiated coverage on Heartflow with a new price target

    Piper Sandler initiated coverage of Heartflow with a rating of Overweight and set a new price target of $38.00

    9/2/25 8:37:45 AM ET
    $HTFL
    Medical/Dental Instruments
    Health Care

    Stifel initiated coverage on Heartflow with a new price target

    Stifel initiated coverage of Heartflow with a rating of Buy and set a new price target of $35.00

    9/2/25 8:37:35 AM ET
    $HTFL
    Medical/Dental Instruments
    Health Care

    $HTFL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Healthcor Partners Management Lp converted options into 6,697,556 shares (SEC Form 4)

    4 - Heartflow, Inc. (0001464521) (Issuer)

    8/22/25 5:15:59 PM ET
    $HTFL
    Medical/Dental Instruments
    Health Care

    SEC Form 3 filed by new insider Healthcor Partners Management Lp

    3 - Heartflow, Inc. (0001464521) (Issuer)

    8/22/25 5:13:10 PM ET
    $HTFL
    Medical/Dental Instruments
    Health Care

    Large owner Bain Capital Life Sciences Investors, Llc converted options into 12,448,158 shares (SEC Form 4)

    4 - Heartflow, Inc. (0001464521) (Issuer)

    8/13/25 4:00:11 PM ET
    $HTFL
    Medical/Dental Instruments
    Health Care